Investor Presentation • Sep 2, 2020
Investor Presentation
Open in ViewerOpens in native device viewer
September 2nd, 2020
Hilja Ibert, CEO
This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the "Company" or "Gentian"). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The information herein and any other material discussed is subject to change. The presentation contains certain forward-looking statements relating to the business, future financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. Any forward-looking statements contained herein, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Potential investors are expressly advised that financial projections, such as the revenue and cash flow projections contained herein, cannot be used as reliable indicators of future revenues or cash flows. Neither the Company (nor any of its parent or subsidiary undertakings) or the Managers (or any such person's representatives, officers, employees or advisors) provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecasted developments. No obligation is assumed to update any forward-looking statements or to conform these forward-looking statements to our actual results. Nothing in this presentation shall constitute an offer to sell or a solicitation of an offer to buy any shares in the Company in any otherwise expressly indicated, this presentation speaks as of the date set out on its cover. In addition, no responsibility or liability or duty of care is or will be accepted by the Company for updating this presentation (or any additional information), correcting any
The distribution of this presentation may also in other jurisdictions be restricted by law. Accordingly, this presentation may not be distributed in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations. The Company require persons in possession of this presentation to inform themselves about, and to observe, any such restrictions.
jurisdiction in which such offer or solicitation is unlawful.
Nothing contained in this presentation is or should be relied upon as a promise or representation as to the future. Except where inaccuracies in it which may become apparent or providing any additional information.
Moving immunoassays to clinical chemistry: Making them available for high-throughput and cost effective instruments
IVD Reagent Market 2018 65B USD/2023 78B USD CAGR : 4% Source: Kalorama, 2018
Global Diagnostics Companies
roll-out and acceptance of product
Distributors serve directly
Healthcare providers
institutions in selected markets
| Sales revenues - | geographic split | |||
|---|---|---|---|---|
| MNOK | 2Q20 | 2Q19 | 1H20 | 1H19 |
| US | 1.0 | 0.6 | 1.7 | 1.1 |
| Europe | 9.9 | 7.7 | 21.1 | 15.1 |
| Asia | 5.7 | 1.9 | 10.1 | 4.6 |
| Total | 16.6 | 10.2 | 32.9 | 20.8 |
| Sales revenues - | product split | |||
| MNOK | 2Q20 | 2Q19 | 1H20 | 1H19 |
| Cystatin C | 8.5 | 3.9 | 15.0 | 8.6 |
| fCAL® turbo | 3.9 | 3.0 | 9.2 | 6.9 |
| Other | 4.3 | 3.3 | 8.7 | 5.3 |
| Total | 16.6 | 10.2 | 32.9 | 20.8 |
| fCAL® turbo | 3.9 | 3.0 | 9.2 | 6.9 |
|---|---|---|---|---|
| Other | 4.3 | 3.3 | 8.7 | 5.3 |
| Total | 16.6 | 10.2 | 32.9 | 20.8 |
| MNOK | 1H 2020 | 1H 2019 |
|---|---|---|
| Sales | 32.9 | 20.8 |
| Other Revenues |
6.1 | 3.4 |
| Total Revenues | 39.0 | 24.2 |
| COGS | 16.2 | 12.0 |
| R&D Costs | 10.7 | 9.3 |
| SG&A | 17.5 | 14.6 |
| Capitalization | -0.6 | -1.4 |
| OPEX | 43.7 | 34.6 |
| EBITDA | -4.7 | -10.4 |
| EBIT | -7.8 | -27.9 |
| Operating activities | 1.1 | - 9.7 |
- 23.1 |
||||
|---|---|---|---|---|---|---|---|
| Investing activities |
- 1.2 |
- 0.4 |
- 4.7 |
||||
| Financing activities |
- 0.1 |
- 0.1 |
0.7 | ||||
| Changes in cash and cash equivalent | - 0.2 |
- 10.2 |
-27.1 | ||||
| Cash and cash equivalent at the beginning of period |
161.4 | 171.6 | 198.6 | ||||
| Cash and cash equivalent at the end of period |
161.2 | 161.4 | 171.6 | ||||
The first turbidimetric antibody/serology test for SARS-CoV-2
The graph below shows the correlation between the same patient samples measured on the Mindray BS400 and Abbott Architect c4000 clinical analyzers (same reagents and calibrators used on both instruments).
This is the first time that a turbidimetric method shows consistent values for this kind of biomarker below 1000 ng/L.
HQ GENTIAN AS
GENTIAN DIAGNOSTICS AB
GENTIAN USA INC.
BEIJING REP. OFFICE Chaoyangmen Outer St Jia No.10 Chaoyang District, Beijing, China
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.